Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma.

ABSTRACT:

Purpose of review

Chimeric antigen receptor (CAR) T cell therapy has been successful in some haematologic malignancies, but the central nervous system (CNS) presents unique obstacles to its use against tumours arising therein. This review discusses recent improvements in the delivery and design of these cells to improve the efficacy and safety of this treatment against malignant gliomas.

Recent findings

The immunosuppressive environment of the CNS affects the functionality of CAR T cells, but recent developments using metabolic manipulation and cytokine delivery have shown that the performance of CAR T cells can be improved in this environment. Emerging techniques can improve the delivery of CAR T cells to the CNS parenchyma, which is normally well protected from peripheral

SUBMITTER: Watchmaker PB 

PROVIDER: S-EPMC9560977 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature